B. Riley Brokers Increase Earnings Estimates for Vaxart

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Analysts at B. Riley boosted their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their previous estimate of ($0.09). B. Riley currently has a "Buy" rating and a $2.00 target price on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart's Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.19 million during the quarter, compared to analysts' expectations of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Vaxart Stock Up 8.3 %

NASDAQ:VXRT traded up $0.03 during mid-day trading on Monday, reaching $0.38. The company's stock had a trading volume of 2,600,245 shares, compared to its average volume of 2,396,652. Vaxart has a 1 year low of $0.34 and a 1 year high of $1.30. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.68. The firm has a market capitalization of $86.44 million, a PE ratio of -0.92 and a beta of 1.57.

Institutional Investors Weigh In On Vaxart

Several large investors have recently modified their holdings of VXRT. Graham Capital Management L.P. increased its holdings in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after buying an additional 32,482 shares during the period. Sequoia Financial Advisors LLC increased its holdings in shares of Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 35,213 shares during the period. Invesco Ltd. raised its position in shares of Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 24,803 shares in the last quarter. XTX Topco Ltd raised its position in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock worth $116,000 after acquiring an additional 122,387 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 17,942 shares during the last quarter. Institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.